Tissue factor pathway inhibitor-2 induced hepatocellular carcinoma cell differentiation

详细信息    查看全文

• 作者：Ziwei Li^a ; Yong Xu^b ; Qin Wang^a ; Changli Xie^a ; Yincui Liu^a ; Zhiguang Tu^a ; ^{tuzhiguang@aliyun.com}
• 关键词：Tissue factor pathway inhibitor 2 ; Differentiation ; Hepatocellular carcinoma ; Apoptosis ; Cell proliferation
• 刊名：Saudi Journal of Biological Sciences
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：24
• 期：1
• 页码：95-102
• 全文大小：1098 K
• 卷排序：24

文摘

To investigate the effect of over-expression of tissue factor pathway inhibitor-2 (TFPI-2) on the differentiation of hepatocellular carcinoma (HCC) cells (Hep3B and HepG2). The TFPI-2 recombinant adenovirus (pAd-TFPI-2) was constructed using the pAdeasy-1 vector system. Transfected by pAd-TFPI-2, the cell proliferation of HCC cells was evaluated by CCK-8 assay, flow cytometry was used to detect cell apoptosis and CD133 expression. Real-time PCR and Western blot were used to detect the expression levels of markers of hepatocellular cancer stem cells (CSC) and hepatocytes. The over-expression of TFPI-2 significantly suppressed cell proliferation, induced apoptosis, and dramatically decreased the percentage of CD133 cells, which was considered as CSC in HCC. Real-time PCR and Western blot showed that the expression of markers of CSC in Hep3B cells and HepG2 cells infected with pAd-TFPI-2 was markedly lower than those of the control group (P < 0.05), while the expression of markers of hepatocytes was significantly increased (P < 0.05). Hence, TFPI-2 could induce the differentiation of hepatocellular carcinoma cells into hepatocytes, and is expected to serve as a novel way for the treatment of HCC.